Though adjuvant remedy regimens, similar to ado-trastuzumab emtansine (T-DM1; Kadcyla) or trastuzumab (Herceptin) plus paclitaxel, have improved outcomes for sufferers with HER2-positive, early-stage breast most cancers, creating extra personalised remedy approaches on this setting might assist spare sure sufferers from pointless toxicity or decide which sufferers require escalated or de-escalated remedy, in line with Sara M. Tolaney, MD, MPH.
“When fascinated about how we additional tailor remedy on this period…I’ve taken the strategy that we want to consider utilizing much less [treatment] or less-toxic remedy in sufferers we are able to choose for higher outcomes,” Tolaney mentioned throughout a presentation on the twenty third Annual Worldwide Congress on the Way forward for Breast Most cancers® East.1
In her presentation, Tolaney outlined de-escalated and less-toxic remedy approaches for sufferers with early-stage HER2-positive breast most cancers; detailed how a pathological full response (pCR) to neoadjuvant remedy might inform personalised remedy approaches; and highlighted the function of biomarkers in individualizing care plans.
Tolaney is a senior doctor, chief of the Division of Breast Oncology, and affiliate director of the Susan F. Smith Heart for Girls’s Cancers at Dana-Farber Most cancers Institute, and an affiliate professor of drugs at Harvard Medical Faculty in Boston, Massachusetts.
Exploring De-escalated, Higher-Tolerated Therapy Choices
Tolaney defined that information have demonstrated that much less remedy might nonetheless present comparable outcomes for sufferers with stage I HER2-positive breast most cancers. Particularly, she highlighted the abbreviated use of chemotherapy, shorter durations of trastuzumab, and the omission of anthracyclines from chemotherapy regimens as areas of alternative.
“Trastuzumab has modified the pure historical past of HER2-positive breast most cancers, the place it was as soon as regarded as the subtype of breast most cancers related to the worst outcomes,” Tolaney mentioned. “Now, it’s [potentially] heading towards the perfect outcomes—a minimum of the outcomes [of these patients] do appear on par with [those who have] HER2-negative illness.”
Regardless of the improved outcomes within the early-stage setting for sufferers with HER2-positive breast most cancers, Tolaney famous that roughly 15% to twenty% of this inhabitants will nonetheless expertise illness recurrence, underscoring the necessity to additional enhance remedy approaches.
Tolaney highlighted 10-year follow-up information from the section 2 APT trial (NCT00542451), which confirmed that sufferers with HER2-positive, estrogen receptor–optimistic or –detrimental, node-negative breast most cancers whose tumors have been not more than 3 cm in dimension (n = 406), skilled a 10-year invasive disease-free survival (iDFS) fee of 91.3% (95% CI, 88.3%-94.4%). Nevertheless, Tolaney cautioned about finish level choice in early-stage breast most cancers trials. Notably, throughout APT, solely 6 distant metastases occasions occurred, and the 10-year recurrence-free interval (RFI) fee—comprised of locoregional recurrence, distant recurrence, and any loss of life from breast most cancers—was 96.3% (95% CI, 94.3%-98.3%).2
“Generally, if somebody has stage I [HER2-positive] illness, giving trastuzumab plus paclitaxel leads to good outcomes,” Tolaney mentioned. “Nevertheless, there are in all probability lots of sufferers who don’t want any remedy, and there could also be a number of sufferers who may wish extra.”
She additional defined that outcomes from APT confirmed that de-escalation trials could be practice-changing provided that there are only a few recurrences. Moreover, research like this can not establish sufferers who don’t want systemic remedy, and finish level choice in trials with low anticipated occasion charges are essential, making recurrence-free interval (RFI) an affordable finish level for de-escalation research.
The section 2 ATEMPT trial (NCT01853748) investigated the potential function for T-DM1 in sufferers with stage I HER2-positive breast most cancers, the place enrolled sufferers have been randomly assigned 3:1 to obtain T-DM1 (n = 383) or trastuzumab plus paclitaxel (n = 114). Notably, the research was not powered to match efficacy between the two arms, though investigators did look at variations in clinically related toxicities (CRTs) between the regimens.3
Information confirmed the 5-year iDFS and RFI charges within the T-DM1 arm have been 97.0% (95% CI, 95.2%-98.7%) and 98.3% (95% CI, 97.0%-99.7%), respectively. Tolaney defined that there was not a distinction within the incidence of CRTs between the two arms; nevertheless, variations within the kinds of opposed results have been noticed. Notably, sufferers handled with trastuzumab plus paclitaxel skilled a better fee of grade 2 or greater neurotoxicity vs T-DM1 (23% vs 11%). T-DM1 was related to a better fee of toxicity resulting in early discontinuation vs trastuzumab plus paclitaxel (17% vs 6%).
Regardless of no variations noticed in CRTs, patient-reported outcomes (PROs) favored T-DM1. Sufferers within the trastuzumab plus paclitaxel arm reported a decline in high quality of life (QOL) through the first 3 months of remedy, and QOL for sufferers handled with T-DM1 was greater at some stage in the research.
“One lesson realized [from ATEMPT] is that you could’t measure the whole lot by these finish factors. PROs are vital to understanding how sufferers are tolerating remedy,” Tolaney mentioned. “Once we requested sufferers [in ATEMPT] about QOL, these measures have been significantly better within the T-DM1 arm in contrast with trastuzumab plus paclitaxel. [Patients also] don’t lose their hair with T-DM1, which makes an enormous distinction to sufferers as effectively.”
Concerning the potential de-escalation of trastuzumab in sufferers with stage I illness, Tolaney famous that 1 12 months of adjuvant remedy stays the SOC. She mentioned that extra work is required to see whether or not a shorter length of remedy wouldn’t diminish efficacy on this affected person inhabitants. The continuing section 2 ATEMPT 2.0 trial (NCT04893109) is evaluating 6 cycles of T-DM1, adopted by 11 cycles of trastuzumab, vs SOC trastuzumab plus paclitaxel, as adjuvant remedy for sufferers with stage I, HER2-positive breast most cancers.
The continuing section 2 STOP-HER2 trial (NCT05721248) is randomly assigning sufferers with HER2-positive early-stage breast most cancers who achieved pCR following neoadjuvant chemotherapy plus HER2-directed remedy to obtain 1 12 months of adjuvant remedy with trastuzumab with or with out pertuzumab (Perjeta), or 6 months of adjuvant trastuzumab with or with out pertuzumab.
Tolaney highlighted one space of remedy de-escalation already explored within the early-stage, HER2-positive setting: the omission of anthracyclines. She spotlighted information from the section 3 BCIRG006 (NCT00021255) and TRAIN-2 (NCT01996267) trials, which confirmed that comparable outcomes could be achieved with taxane-based remedy vs anthracycline-based remedy, together with in sufferers with high-risk, node-positive illness.
“I’ve stopped using anthracyclines in HER2-positive illness. We see much less cardiac toxicity, much less secondary leukemias, and I do not assume [anthracyclines] are bettering outcomes,” Tolaney mentioned.
Utilizing pCR to Inform Therapy Approaches
Tolaney defined that the continued purpose within the early-stage HER2-positive breast most cancers area is to make use of response to neoadjuvant remedy as a information for additional remedy choices. She spotlighted information from the section 3 KATHERINE trial (NCT01772472), which evaluated adjuvant T-DM1 vs trastuzumab in sufferers who had residual invasive tumors within the breast or axillary nodes.
Within the ultimate evaluation of the trial, which had a median follow-up of 8.4 years, T-DM1 (n = 743) led to a 46% discount within the danger of an iDFS occasion vs trastuzumab (n = 743; HR, 0.54; 95% CI, 0.44-0.66; P < .0001). The 7-year iDFS charges have been 80.8% for T-DM1 vs 67.1% for trastuzumab.4
Regardless of the information from KATHERINE, Tolaney mentioned there stays a must proceed bettering outcomes. Notably, sufferers in KATHERINE who had node-positive illness have been at a better danger of recurrence, and there was a scarcity of enchancment in central nervous system recurrence with T-DM1.
“In my thoughts, it is extremely vital to present all sufferers with stage II or III illness preoperative remedy with the intention to tailor [adjuvant] remedy as a result of it’s impacting survival outcomes,” Tolaney mentioned. “Though [KATHERINE] has been a pivotal, practice-changing research, there are nonetheless questions that stay.”
The COMPASSHER2 trials, comprised of the section 2 CompassHER2-pCR research (NCT04266249) and the section 3 CompassHER2 RD research (NCT04457596), are treating sufferers primarily based on pCR standing following neoadjuvant remedy and surgical procedure. These with a pCR are enrolled to CompassHER2-pCR to obtain 1 12 months of trastuzumab plus pertuzumab, with radiation and endocrine remedy given if applicable. These with out a pCR are continuing to CompassHER2 RD, the place they’re being randomly assigned to T-DM1 or T-DM1 plus tucatinib (Tukysa).
Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) can also be being investigated as adjuvant remedy within the section 3 DESTINY-Breast05 trial (NCT04622319). Sufferers with early-stage HER2-positive breast most cancers who’ve residual illness following neoadjuvant chemotherapy and HER2-directed remedy are being randomly assigned to T-DXd or T-DM1.
Tolaney additionally pointed to neratinib (Nerlynx) as a doable escalation possibility within the adjuvant setting. She defined advantages have been noticed in sufferers with high-risk, hormone receptor–optimistic, HER2-positive illness who’ve residual illness after preoperative remedy. She cautioned that the section 3 EXTENET trial (NCT00878709), which evaluated 1 12 months of neratinib vs placebo in sufferers who obtained prior adjuvant trastuzumab, was performed previous to the combination of adjuvant pertuzumab and T-DM1 into the SOC. Neratinib has additionally been related to grade 3/4 diarrhea in roughly 40% of sufferers, and Tolaney emphasised the necessity for prophylactic remedy or a dose-escalation strategy with neratinib.
“I usually will solely take into consideration [using neratinib] in somebody who has high-risk, residual, hormone receptor–optimistic, [HER2-positive] illness.”
Rising Biomarkers in Early-Stage HER2-Constructive Breast Most cancers
Past utilizing pCR as a information for remedy choices, different biomarkers might assist tailor up-front remedy, Tolaney mentioned. The HER2DX genomic take a look at is designed to guage 27 genes and 4 gene signatures: immune/B-cell, proliferation, luminal differentiation, and HER2 amplicon expression. By analyzing these genes, the take a look at gives a relapse danger rating, a pCR probability rating, and an ERBB2 mRNA rating.
“HER2DX is one assay that has some promise as a result of it will provide you with the danger of getting a recurrence or the [potential] of attaining a pCR with a selected remedy,” she mentioned. “It’s an assay that’s getting additional validated. There have been plenty of trials the place it’s been examined, and the meta-analysis that was finished did present that it was capable of separate outcomes primarily based on the danger rating, which has been fairly promising.”
Tolaney painted a state of affairs the place HER2DX might be utilized to find out up-front remedy. If a affected person had a medium potential of attaining a pCR, she mentioned a multi-agent chemotherapy routine might be thought-about. Conversely, if a affected person had a excessive chance of experiencing a pCR, it might be doable to make use of 1 chemotherapy agent plus twin HER2-targeted remedy within the neoadjuvant setting, she mentioned.
Tolaney concluded by highlighting her present view of the remedy algorithm for sufferers with early-stage HER2-positive breast most cancers. In sufferers with T≤1 cm and cN0 illness, she is going to proceed on to surgical procedure, adopted by adjuvant trastuzumab plus paclitaxel for these with stage I illness or docetaxel plus carboplatin and trastuzumab with or with out pertuzumab for these with stage II or III illness. If sufferers current with T>1 cm and ≤2 cm illness, she is going to conduct an axillary ultrasound to find out whether or not neoadjuvant remedy is critical. In these with T>2 cm and/or node-positive illness, the SOC is neoadjuvant docetaxel plus carboplatin, trastuzumab, and pertuzumab, adopted by adjuvant trastuzumab plus pertuzumab in sufferers who obtain a pCR, or adjuvant T-DM1 in these with residual illness.
“If [patients] have node-positive or bigger [tumors], they want preoperative remedy, after which you’ll be able to alter [adjuvant therapy] primarily based on response on the time of surgical procedure,” Tolaney concluded.
References
- Tolaney SM. New insights into optimizing HER2-directed remedy within the healing setting. Introduced at: twenty third Annual Worldwide Congress on the Way forward for Breast Most cancers East; July 19-20, 2024; New York, NY.
- Tolaney SM, Tarantino P, Graham N, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast most cancers: ultimate 10-year evaluation of the open-label, single-arm, section 2 APT trial. Lancet Oncol. 2023;24(3):273-285. doi:10.1016/S1470-2045(23)00051-7
- Tolaney SM, Hu J, Dang C, et al. A randomized section II research of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) together with trastuzumab (H) for stage I HER2-positive breast most cancers (BC) (ATEMPT). Introduced at: 2019 San Antonio Breast Most cancers Symposium; December 10-14, 2019; San Antonio, TX. Summary GS1-05.
- Loibl S, Mano M, Untch M, et al. Part III research of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast most cancers after neoadjuvant chemotherapy and HER2-targeted remedy: KATHERINE ultimate IDFS and up to date OS evaluation. Introduced at: 2023 San Antonio Breast Most cancers Symposium; December 5-9, 2023; San Antonio, TX. Summary GS03-12
